Gene Therapy for WAS

计划入组 5 人 · 首次发布于 2011 年 5 月 4 日

Gene Therapy for Wiskott-Aldrich Syndrome (WAS)

计划入组 6 人 · 首次发布于 2011 年 5 月 4 日

Elevated Initial APRI Value Was Associated With SALD

计划入组 160 人 · 首次发布于 2023 年 8 月 21 日

WAS Protein Stabilizers (XL Therapeutics)

Trecadrine

Wiskott-Aldrich syndrome gene therapy (Genethon)

Protein Sciences Corporation

United States

HOUSE OF SUPPLEMENTS AUSTRALIA PTY LTD

Australia

Arvinas

United States

EMA Recommends First Gene Therapy for Wiskott-Aldrich Syndrome

FDA Approves First Gene Therapy for Wiskott-Aldrich Syndrome

Fabhalta Demonstrates Sustained Efficacy in Phase III C3 Glomerulopathy Trial